Annual report pursuant to Section 13 and 15(d)

Organization and Nature of Business - Additional Information (Detail)

v3.20.2
Organization and Nature of Business - Additional Information (Detail) - USD ($)
$ in Thousands
Dec. 18, 2019
Mar. 31, 2020
Dec. 17, 2019
Mar. 31, 2019
Cash   $ 100,571   $ 6,985
Accumulated deficit [1]   $ (91,226)   $ (24,838)
Series A Preferred Stock [Member]        
Number of shares issued in business combination 10,000      
Roivant Sciences Ltd. [Member] | Series A Preferred Stock [Member]        
Number of shares issued in business combination 10,000      
Immunovant Sciences Ltd [Member]        
Percentage of business acquisition 100.00%      
Number of shares issued in business combination 42,080,376      
Shares exchange ratio 0.48907%      
Immunovant Sciences Ltd [Member] | Sellers [Member]        
Ownership percentage     100.00%  
[1] Retroactively restated for the reverse recapitalization as described in Note 1.